Red Cat CEO Jeff Thompson to Present at TD Cowen's 46th Annual Aerospace & Defense Conference
SAN JUAN, Puerto Rico, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) ('Red Cat') ('Red Cat'), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced that its Chief Executive Officer, Jeff Thompson, will present at TD Cowen's 46th Annual Aerospace & Defense Conference on Wednesday, February 12, 2025.
Thompson's presentation is scheduled from 1:20 PM to 2:00 PM ET in Track 2 (Salon II, Conference Level) at The Ritz-Carlton, Pentagon City in Arlington, VA. He will discuss Red Cat's latest advancements in drone technology and the company's strategic initiatives within the aerospace and defense sectors.
TD Cowen's 46th Annual Aerospace & Defense Conference, taking place February 11-13, 2025, brings together industry leaders for a series of presentations, fireside chats, and panel discussions. Moderated by members of the TD Cowen research team, the event will highlight key trends shaping the aerospace and defense industries.
Investors and attendees interested in scheduling a one-on-one meeting with Mr. Thompson are encouraged to contact the Company through the investor relations section of the Red Cat website.
About Red Cat Holdings, Inc.
Red Cat (Nasdaq: RCAT) is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Through two wholly owned subsidiaries, Teal Drones and FlightWave Aerospace, Red Cat has developed a Family of Systems. This includes the Black Widow™, a small unmanned ISR system that was awarded the U.S. Army's Short Range Reconnaissance (SRR) Program of Record contract. The Family of Systems also includes TRICHON™, a fixed wing VTOL for extended endurance and range, and FANG™, the industry's first line of NDAA compliant FPV drones optimized for military operations with precision strike capabilities. Learn more at www.redcat.red.
About TD Securities
As a leading corporate and investment bank, TD Securities offers a wide range of integrated capital markets products and services. Our corporate, government, and institutional clients choose us for our innovation, execution, and experience.
With more than 7,100 professionals operating out of 34 cities across the globe, we help clients meet their needs today and prepare for tomorrow. Our services include underwriting and distributing new issues, providing trusted advice and industry-leading insight, extending access to global markets, and delivering integrated transaction banking solutions.
TD Cowen is a division of TD Securities. As part of TD Securities' broader suite of integrated capital markets products and services, our offering includes investment banking, research, sales and trading, prime brokerage, outsourced trading, and commission management services.
We are growth-oriented, people-focused, and community-minded. As a team, we work to deliver value for our clients every day.
Forward Looking Statements
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Red Cat Holdings, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Form 10-K filed with the Securities and Exchange Commission on July 27, 2023. Forward-looking statements contained in this announcement are made as of this date, and Red Cat Holdings, Inc. undertakes no duty to update such information except as required under applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Cantor Fitzgerald Initiates Coverage on Docebo (DCBO) With an Overweight Rating
Docebo Inc. (NASDAQ:DCBO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, analyst Yi Fu Lee from Cantor Fitzgerald initiated coverage on Docebo Inc. (NASDAQ:DCBO) assigning an Overweight rating with a price target of $35 on the stock. This marks the first rating on the stock from Cantor Fitzgerald indicating firms' confidence in the company's potential and the overall industry condition. Docebo Inc. (NASDAQ:DCBO) is a leading learning platform that uses AI and innovation as its backbone. The company announced results for its fiscal first quarter of 2025 on March 9. The subscription revenue grew 13% year-over-year to $54.2 million, representing 95% of the total revenue. Whereas the total revenue also grew 11% year-over-year to $57.3 million. Notably, net income came in at $1.5 million. Both the revenue and EPS exceed market expectations, with revenue beating the consensus by $0.2 million and EPS topped by $0.05. A professional instructor delivering a customer education workshop. Management is anticipating second-quarter revenue between $59.0 million and $59.2 million. It expects subscription revenue to grow about 1.5% higher than overall company revenue. Docebo Inc. (NASDAQ:DCBO) provides an AI-powered learning platform that helps organizations create, manage, and deliver personalized training programs at scale. The company's platform enables organizations to deliver advanced learning experiences for its employees to drive measurable growth. While we acknowledge the potential of DCBO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
20 minutes ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
23 minutes ago
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
